
FDA weighs standard access for women's testosterone therapy amid off-label use
There is no FDA-approved testosterone product for women, so clinicians rely on off-label or compounded regimens to treat menopausal symptoms such as low sexual desire, leading to dosing, safety, and insurance challenges; an FDA workshop is reviewing evidence gaps and safety to determine whether standardized access and guidelines are feasible, spurred by patient and clinician advocacy.












